Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms

• Weighing up novel payload development through evolving existing payload classes versus pursuing novel mechanisms
• Leveraging new and advanced tools to investigate novel tubulin payload development
• Contextualising payload innovation through ADC programmes and understanding significance for nextgeneration ADC development

Speakers:

Christian Rohlff

Chief Executive Officer

Oxford BioTherapeutics